Search Results - Yongqian Shu
-
1
Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk.
Published 2013-01-01Get full text<h4>Background</h4>Interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, is emerging as a key mediator of carcinogenesis that characterizes host-environment interactions. Epidemiological studies investigating the association between two polymorphisms of IL-1B (-511C/T and +3954C/T) an...
Article -
2
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Published 2013-01-01Get full text<h4>Background</h4>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). The studies are quite heterogenous regarding study size and populatio...
Article -
3
Expression and clinical significance of S100A8/9 in adults with secondary phagocytic lymphohistiocytosis
Published 2025-07-01Get full textIntroductionThe study aimed to investigate the diagnostic and prognostic value of serum S100A8/9 levels with sHLHa, a high-mortality multiorgan inflammatory syndrome with no reliable clinical biomarkers, where calreticulin’s role is unclear.MethodsThis was a study of 67 newly diagnosed sHLHa patient...
Article -
4
Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China
Published 2018-06-01Get full textAbstract Dysregulated microRNAs (miRNAs) in the plasma of patients with lung squamous cell carcinoma (LSCC) might serve as biomarkers for LSCC diagnosis. The expression of miRNAs was performed using quantitative reverse transcription–polymerase chain reaction (qRT‐PCR) on the basis of Exiqon panels...
Article